Dr. Yaohan Lam, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Oklahoma College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 854
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Oklahoma College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
OK license 27838
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Yaohan Lam Dermatology PLLC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 854
- Services billed
- 3,289
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,130 | 172 |
| Established patient office or other outpatient visit, 20-29 minutes | 526 | 408 |
| Destruction of precancer skin growth, 1 growth | 283 | 233 |
| Biopsy of related skin growth, first growth | 209 | 186 |
| Established patient office or other outpatient visit, 30-39 minutes | 143 | 109 |
| New patient office or other outpatient visit, 30-44 minutes | 119 | 119 |
| Established patient office or other outpatient visit, 10-19 minutes | 92 | 80 |
| Destruction of precancer skin growth, 15 or more growths | 58 | 48 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 53 | 48 |
| New patient office or other outpatient visit, 15-29 minutes | 51 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 133 payments worth $33,352 in total to this clinician.
| Lilly USA, LLC | $22,766 |
|---|---|
| Incyte Corporation | $9,209 |
| Janssen Biotech, Inc. | $255 |
| Leo Pharma Inc. | $183 |
| Novartis Pharmaceuticals Corporation | $178 |
| Arcutis Biotherapeutics, Inc. | $175 |
| Genzyme Corporation | $134 |
| AbbVie Inc. | $118 |
| Compensation for services other than consulting (speaking, faculty) | $29,850 |
|---|---|
| Food and Beverage | $2,029 |
| Travel and Lodging | $1,274 |
| Education | $198 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) Opzelura · Dermatology | $7,200 |
| Lilly USA, LLC Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Oct 27, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,750 |
| Lilly USA, LLC Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,750 |
| Lilly USA, LLC Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
All 28 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Oct 27, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Oct 27, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $750 |
| Incyte Corporation Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) Opzelura · Dermatology | $600 |
| Lilly USA, LLC Sep 24, 2025 | Travel and Lodging EBGLYSS · Immunology · travel to KANSAS CITY, MO | $30.00 |
| Lilly USA, LLC Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,750 |
| Lilly USA, LLC Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Sep 4, 2025 | Travel and Lodging travel to KANSAS CITY, MO · in-kind | $182 |
| Janssen Biotech, Inc. Aug 20, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| Lilly USA, LLC Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
| Lilly USA, LLC Jul 23, 2025 | Travel and Lodging EBGLYSS · Immunology · travel to SANDESTIN, FL | $30.00 |
| Lilly USA, LLC Jul 23, 2025 | Travel and Lodging EBGLYSS · Immunology · travel to SANDESTIN, FL | $4.00 |
| Lilly USA, LLC Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,750 |
| Lilly USA, LLC Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Jul 15, 2025 | Travel and Lodging travel to SANDESTIN, FL · in-kind | $335 |
| Lilly USA, LLC Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
| Lilly USA, LLC May 22, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
| Incyte Corporation May 16, 2025 | Compensation for services other than consulting (speaking, faculty) Opzelura · Dermatology | $300 |
| Lilly USA, LLC May 9, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $500 |
| Incyte Corporation Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) Opzelura · Dermatology | $7,200 |
| Janssen Biotech, Inc. Apr 15, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| Incyte Corporation Apr 5, 2025 | Travel and Lodging Opzelura · Dermatology · travel to Rosemont, IL | $238 |
| Incyte Corporation Apr 4, 2025 | Travel and Lodging Opzelura · Dermatology · travel to Rosemont, IL | $405 |
| Incyte Corporation Apr 4, 2025 | Travel and Lodging Opzelura · Dermatology · travel to Oklahoma City, OK | $50.00 |
| Lilly USA, LLC Feb 13, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
| Lilly USA, LLC Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $357,171 in research payments for these studies, mostly to the institutions running them.
- A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
UCB SA · Completed · NCT05277571 - A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Incyte Corporation - A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-nave Metastatic Castration-resistant Prostate Cancer
Amgen Inc. - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Mod…
Janssen Research & Development, LLC - Observation priority e short - lebrikizumab - atopic dermatitis
Eli Lilly and Company - A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream
Incyte Corporation - A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis
Incyte Corporation - A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Incyte Corporation - A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria
Incyte Corporation - A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK)
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.